At a glance
ClinicalIndex Comparison RecordN/ACompleted· 90 enrolled
Drug / intervention
Alloderm +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction: A Blinded, Prospective, Randomized, Controlled Trial
In Brief
A clinical study evaluating Alloderm and Surgimend for Breast Cancer. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if the complication rate and post-surgical appearance differ based on what type of mesh is used for breast reconstruction surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedMar 2011
Primary CompletionNov 2017
TodayJul 2026
First PostedMar 7, 2011
Enrollment StartFeb 1, 2011
Primary CompletionNov 8, 2017
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 15.3 years ago
Interventions
Allodermdevice
6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
Surgimenddevice
10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.